Clinical Trial Update: Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS) [Phase 2]

View source ↗

Summary

Phase 2 trial of BI 54903 inhaled corticosteroid for asthma inadequately controlled on low-dose ICS; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• BI 54903

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Asthma | Phase 2 | Status: TERMINATED | Results posted: 2022-06-23